Alpha Cognition Inc
ACOG
주식 순위
#20188
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
주가
$8.47
마지막 동기화: 2026-10-19
시가총액
$131.47M
변동 (1일)
3.36%
변동 (1년)
68.29%
국가
US
거래 Alpha Cognition Inc (ACOG)
카테고리
Healthcare
Alpha Cognition Inc (ACOG)의 P/B 비율
October 2026 기준 P/B 비율 TTM: -114.63
Alpha Cognition Inc의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 -114.63입니다. 2022년 말 기준 P/B 비율은 -274.94였습니다.
Alpha Cognition Inc의 P/B 비율 기록 (2018 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | -114.63 | -53.90% |
| 2023 | -248.67 | -9.55% |
| 2022 | -274.94 | -288.08% |
| 2021 | 146.19 | -97.93% |
| 2020 | 7.05K | 6,164.26% |
| 2019 | 112.47 | 16.25% |
| 2018 | 96.75 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | -105.45% |
US
|
|
| 13.2547 | -111.56% |
US
|
|
| 4.208 | -103.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -105.39% |
NL
|
